General Information
Sanofi Aventis 6911
A multicenter, randomized, placebo-controlled, 'factorial' design, 12-month study to evaluate the efficacy and safety of AVE5530 25mg/day and 50mg/day co-administered with all registered atorvastatin strengths ranging from 10mg to 80mg in patients with primary hypercholesterolemia
| Protocol | EFC6911 |
|---|---|
| Identifier | EFC6911 |
| UID | c62349fc-53f2-43c5-8419-6b293c7b1f59 |
| Status | Done - Archived |
| Phase | 3 |
| Category | Schizophrenia / Adult |
| Launch Year | 2008 |
| NCT Number | - |
| Created | 2010-08-03 13:57 |
| Last Updated | 2010-08-03 13:57 |
Description
No description provided.
Comment
No comment.
Target Dates
| Name | Date | Required |
|---|---|---|
| Enrollment Closed | No | |
| Enrollment Open | No | |
| First Patient First Visit | No | |
| Site Initiation Mtg. | 2008-01-01 | No |
| PI Meeting Start | No | |
| PI Meeting End | No | |
| PI Meeting Arrival | No | |
| PI Meeting Departure | No | |
| Closeout Date | 2009-12-01 | No |
| Final PatientVisit | No | |
| PreStudy Selection Visit | No | |
| Target Date 12 | No | |
| Target Date 13 | No | |
| Target Date 14 | No |
Leadership
| Role | Staff | Login | Required |
|---|---|---|---|
| Principal | Zolnouni, Parvaneh | PZolnouni | No |
| Recruiter | - | No | |
| Coordinator | Villegas, Claudia | CVillegas | No |
| Regulatory | Aguirre, Sandra | SAguirre | No |
Custom Fields
No custom fields.
Sponsor & Organization
| Sponsor | Sanofi-Aventis |
|---|---|
| Division | Sanofi-Aventis |
| Team | Sanofi-Aventis |
| Managing Site | Catalina Research Institute, LLC |
| Organization |
Contacts
| IRB Ref | |
|---|---|
| CRO | |
| CRO Ref | |
| Correspondence | 0 |
Opportunity
| Probability | 0 |
|---|---|
| Comment | |
| Status Color | Gainsboro |
| Currency | - |
